Phase 2 × Completed × Lymphoma, Large-Cell, Anaplastic × Clear all Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
348 enrolled 15 charts
Vinorelbine for Recurrent ALCL-2017
Phase 2 Completed
20 enrolled
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Phase 2 Completed
77 enrolled 20 charts
CREATE
Phase 2 Completed
582 enrolled
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
Phase 2 Completed
12 enrolled 8 charts
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Phase 2 Completed
34 enrolled 12 charts
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
Phase 2 Completed
12 enrolled
Vinorelbine for Recurrent ACLC
Phase 2 Completed
20 enrolled
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 2 Completed
41 enrolled 8 charts
Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 2 Completed
109 enrolled
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
Phase 2 Completed
39 enrolled 26 charts
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Phase 2 Completed
6 enrolled 16 charts
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
Phase 2 Completed
93 enrolled 12 charts
Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment
Phase 2 Completed
77 enrolled
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Phase 2 Completed
60 enrolled 10 charts
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
210 enrolled 15 charts
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
94 enrolled 11 charts
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
77 enrolled 12 charts
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
14 enrolled 22 charts
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Phase 2 Completed
16 enrolled 10 charts
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
Phase 2 Completed
5 enrolled 8 charts
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase 2 Completed
25 enrolled 7 charts
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
Phase 2 Completed
59 enrolled
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
Phase 2 Completed
37 enrolled 8 charts
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
12 enrolled 10 charts
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
Phase 2 Completed
43 enrolled 5 charts
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Phase 2 Completed
43 enrolled 14 charts
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Completed
53 enrolled 10 charts
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Phase 2 Completed
58 enrolled 19 charts
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
Phase 2 Completed
239 enrolled 23 charts
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Phase 2 Completed
110 enrolled 15 charts
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
Phase 2 Completed
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Phase 2 Completed
42 enrolled 10 charts
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
14 enrolled 7 charts
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
Phase 2 Completed
80 enrolled
S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Phase 2 Completed
34 enrolled 9 charts
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
Phase 2 Completed
32 enrolled 24 charts
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Phase 2 Completed
25 enrolled
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Phase 2 Completed
22 enrolled 5 charts
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
51 enrolled 14 charts
Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
Phase 2 Completed
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma
Phase 2 Completed
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
Phase 2 Completed
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
Phase 2 Completed
Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Phase 2 Completed
33 enrolled
S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Completed
60 enrolled
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Phase 2 Completed
24 enrolled 13 charts
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
25 enrolled